Can-Fite BioPharma Ltd.
CANFDrugs in Pipeline
8
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Jan 31, 2027
22wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
CF101 2mg
Plaque Psoriasis
CF101
Rheumatoid Arthritis
Namodenoson
Hepatocellular Carcinoma
Piclidenoson
COVID-19
CF 102
Chronic Hepatitis C
CF102
Hepatocellular Carcinoma
Namodenoson 25mg
Pancreatic Adenocarcinoma
CF101 1mg
Plaque Psoriasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CF101 2mg | Phase 3 | Plaque Psoriasis | - | - |
CF101 | Phase 3 | Rheumatoid Arthritis | - | - |
Namodenoson | Phase 3 | Hepatocellular Carcinoma | - | - |
Piclidenoson | Phase 2 | COVID-19 | - | - |
CF 102 | Phase 2 | Chronic Hepatitis C | - | - |
CF102 | Phase 2 | Hepatocellular Carcinoma | - | - |
Namodenoson 25mg | Phase 2 | Pancreatic Adenocarcinoma | - | - |
CF101 1mg | Phase 2 | Plaque Psoriasis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Can-Fite BioPharma Ltd.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Can-Fite BioPharma Ltd.'s (CANF) pipeline across Phase 3, Phase 2. Its lead program is CF101 2mg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Can-Fite BioPharma Ltd.'s next FDA catalyst?→
Can-Fite BioPharma Ltd.'s (CANF) next tracked catalyst is a Phase 3 expected January 31, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CANF biotech catalysts?→
Add CANF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Can-Fite BioPharma Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.